Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMROSE first-in-human AZD3470 study in MTAP-deficient advanced solid tumors
jRCT2031230577Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, randomised, open-label trial in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) comparing AZD3470 monotherapy with AZD3470 + datopotamab deruxtecan (2 arms). Primary endpoints: Incidence of adverse events and serious adverse events, Recommended Phase II dose and 2 more. Started Mar 2024; status: recruiting.
02
Drugs
AZD3470datopotamab deruxtecan
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031230577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230577.